Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

RiboLife-B (瑞博生物) IPO:  High Price Tag

Suzhou Ribo Life Science (瑞博生物) Pre-IPO: PHIP Updates Highlight Asset Prioritization

Suzhou Ribo Life Science (瑞博生物) Pre-IPO: Competition Understated

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Suzhou Ribo Life Science / Equity Capital Markets

<ul>
<li>RiboLife raised HKD 1832m (USD 236m) from its global offering and will list on the Hong Kong Stock Exchange on Friday January 9th, 2026.</li>
<li>In our previous note, we looked at the company's fundamentals and the valuation.</li>
<li>In this note, we provide an update for the IPO before its trading debut.</li>
</ul>


RiboLife raised HKD 1832m (USD 236m) from its global offering and will list on the Hong Kong Stock Exchange on Friday January 9th, 2026.
In our previous note, we looked at the company's fundamentals and the valuation.
In this note, we provide an update for the IPO before its trading debut.


Suzhou Ribo Life Science

RiboLife-B (瑞博生物) IPO Trading